Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
The Indianapolis-based company released more details this month about its Enlist Weed Control System, which would genetically modify corn, soybeans and cotton to be resistant to one of the most common weedkillers.
The Indianapolis-based life insurer pulled in sales last year of $1.7 billion and boosted its overall assets 12 percent, to $24.4 billion.
The state budget bill moving through the Indiana General Assembly would save about $7 million each year by creating a list of preferred mental health drugs and trying to win larger rebates from manufacturers.
Delays getting new diabetes meters into the U.S. market appear to have tripped up Roche Diagnostics Corp. on its way to acquiring a key software vendor.
Aida McCammon has spent 20 years helping Hispanics improve their lives and succeed in the United States.
It’s a wide entitlement program that will literally explode in the coming decades, since a third of all combat veterans will meet the disability requirements. It is not sustainable, and the Senate just tightened the requirements.
Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.
Tony Lennen became president of Community Hospital South in 2009, overseeing a 50-bed expansion that was completed last summer, giving the hospital 150 private rooms. The facility, located along the line between Marion and Johnson counties, competes against nearby facilities run by Franciscan St. Francis Health, Indiana University Health and Johnson Memorial Hospital.
Think galloping health insurance costs are a problem unique to American employers? Think again. Medical costs paid by employer-focused health insurers rose by an average of 10 percent last year—identical to the United States.
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.
R. Glenn Hilliard, 68, who has held the chairman's title since September 2003, said he will not seek re-election.
A Terre Haute pharmacist faces a possible 10-year prison sentence if convicted of health care fraud and money laundering in a scheme that netted him more than $3.57 million.
With the company recently doubling in size, CEO Dayton Molendorp wanted another executive to guide the company’s further growth.
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
The Indianapolis Parks Foundation plans to use a $150,000 grant from Indiana University Health to start an organic farm on the east side of the city benefiting Gleaners Food Bank.
WellPoint Inc. has already more than doubled the enrollment gains it expected in 2011 for national accounts that the health insurer administers for large employers.
The Metropolitan Development Commission awarded the tax abatements for the nursing school, set to open in October, despite opposition from the Nora-Northside Community Council and Metropolitan School District of Washington Township.
Community Health Network won a three-way race for a close partnership with Johnson Memorial Hospital, besting Franciscan St. Francis and Indiana University Health.
Over the next five years, WellPoint Inc. expects the employer-sponsored insurance business to shrink slightly, forcing it to shift its focus to government-sponsored plans.
